Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity

Sato, Tatsuhiko; Wada, Kazuko; Arahori, Hitomi; Kuno, Noriyuki; Imoto, Kenji; Iwahashi-Shima, Chiharu; Kusaka, Shunji

doi:10.1016/j.ajo.2011.07.005

Cited by 303 publications

(230 citation statements)

References 24 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…The presence of systemic detrimental effects following IVB in premature infants remains controversial (26) with no strong evidence of such adverse effects reported to date. In a large cohort study evaluating IVB as a monotherapy in all forms of ROP, the authors posited a positive effect of IVB on systemic parameters in infants, such as early recovery from oxygen dependency and early improvement in nutritional status according to clinical observations (6) .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Günay¹,

Çelik²,

Günay³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Approved by the following research ethics committee: Zeynep Kamil Maternity and Children's Disease Training and Research Hospital. ABSTRACTPurpose: To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP). Methods: Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations. Results: Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively). Conclusions:The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Günay¹,

Çelik²,

Günay³

et al. 2015

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…[7][8][9] Conflicting data were reported with respect to the existence of a contralateral eye effect and the presence of biologically significant levels of anti-VEGF compound in the contralateral eye following unilateral injection. [10][11][12][13][14][15][16] In the clinic setting, bilateral injections may mask such a contralateral effect.…”

Section: Introductionmentioning

confidence: 84%

“…[17][18][19] In humans, it has been well established that anti-VEGF drugs delivered within the vitreous can pass into the systemic circulation. Serum level of VEGF was demonstrated to be reduced after intravitreal bevacizumab injections in infants with retinopathy of prematurity, 8 in patients with neovascular age-related macular degeneration 9 and in patients with type 2 diabetes. 7 In patients with age-related macular degeneration, contralateral intravitreal bevacizumab injection influenced retrobulbar hemodynamic parameters.…”

Section: Discussionmentioning

confidence: 99%

“…Results Thirty-five patients were evaluated. Mean follow-up was 245 days (range: 30-800), and the mean number of bevacizumab injections was 3.6 (range: [1][2][3][4][5][6][7][8][9][10][11]. At end of follow-up, the mean (SD) OCT central subfield thickness reduced by 72±112 micron in the injected eye (from 469 ± 139 to 397 ± 120 micron; P ¼ 0.001), while in the non-injected eye it reduced by 49 ± 75 micron (from 380 ± 130 to 331 ± 106 micron; Po0.001).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema

Hanhart

Tiosano

Averbukh

et al. 2014

Eye

View full text Add to dashboard Cite

“…9 The initial enthusiasm of using bevacizumab monotherapy in zone 1 ROP has been tempered by the probability of its impact on normal ocular angiogenesis, late recurrences as well as its possible effects on many developing organs such as the brain, the kidneys and the lungs owing to the drug reaching the systemic circulation. 2,[13][14][15] In fact, some reports have questioned the use of this medication without clinical trials that mandates meticulous evaluation of multiple variables that normally precedes the introduction of drugs in clinical use. 16 Thus a careful intensive documentation of sequential vascular changes following intravitreal bevacizumab (IVB) is necessary for judicious use in management of ROP.…”

Section: Introductionmentioning

confidence: 99%

Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I

Padhi

Das

Rath

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To evaluate the serial changes in retinal vasculature in infants treated with intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity (APROP) in zone I. Methods Retrospective analysis of serial changes in retinal vasculature after IVB in the seven eyes of four babies with APROP in zone I. Results The initial regression, following IVB, was dramatic with reduction in vessel caliber and marked thinning and invisibility of the bridging shunts. Resurgent vascular development was very slow radially though there was continued abnormal vascular growth circumferentially. Common findings in all eyes were tangled vasculature and fine saw-toothed shunts. The variable findings were (1) new closely packed multilayered bridging shunts, long arching mature looking vessels, and finally a ridge at the periphery (n = 3 eyes) at 52 weeks of postmenstrual age (PMA); (2) status quo at the stage of saw-toothed shunt and ridge in both eyes for a long time (n = 2 eyes); and (3) multiple retinal hemorrhages within the vascularized retina and thick preretinal hemorrhage overlying the saw-toothed shunts and ridge that persisted for another 3 weeks and regressed 2 weeks after laser (n = 1). The eyes that received bevacizumab alone (3) did not show any abnormal vascularization at 56 weeks of PMA or beyond. Conclusions The retinal vascularization following IVB was different than normal in terms of its time, speed, and morphology; few of these changes are first to be reported in the literature (Medline search) and warrants further studies.

show abstract

Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity

Cited by 303 publications

References 24 publications

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema

Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I

Contact Info

Product

Resources

About